GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
Posted
Frank Vinluan (via MedCity News)
The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer
The post GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer appeared first on MedCity News.